Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP4 | P49662 | 1/20 | 0.40 |
| ▸ | CASP5 | P51878 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249609 | 0.98 | CHRM5 (0.62) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL2254261 | 0.93 | CHRM5 (0.56) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL4172195 | 0.84 | CHRM5 (0.52) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL4172196 | 0.84 | CHRM5 (0.52) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL4824721 | 0.83 | CHRM5 (0.84) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL1241238 | 0.83 | CHRM5 (0.84) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL19612775 | 0.83 | CHRM5 (0.84) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL3632436 | 0.83 | CHRM5 (0.84) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL42121 | 0.82 | CHRM5 (0.67) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL20643257 | 0.80 | CHRM5 (1.00) | CHRM5ADRA2CACHESMN1; SMN2CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | claimed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | claimed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | claimed |
| US-9597314-B2 | Beta-lactamylalkanoic acids for treating premenstrual disorders | AZEVAN PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | claimed |
| US-6949541-B2 | Substituted piperidines, medicaments containing these compounds, and methods for the production thereof | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-09-27 | — | — | US | claimed |
| US-20030212057-A1 | Substituted piperidines, medicaments containing these compounds, and methods for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-13 | — | — | US | claimed |
| EP-1252153-A1 | SUBSTITUTED PIPERIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND METHODS FOR THE PRODUCTION THEREOF | Boehringer Ingelheim Pharma KG (DE) | 2002-10-30 | — | — | EP | claimed |
| WO-2001049676-A1 | SUBSTITUTED PIPERIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-07-12 | — | — | WO | claimed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11628160-B2 | Compositions and methods for treating brain injury | AZEVAN PHARMACEUTICALS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | AZEVAN PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20090170825-A1 | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | AZEVAN PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20080280870-A1 | Beta-Lactamyl Phenylalanine, Cysteine, and Serine Vasopressin Antagonists | AZEVAN PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
| US-6949541-B2 | Substituted piperidines, medicaments containing these compounds, and methods for the production thereof | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-09-27 | — | — | US | disclosed |
| US-20030212057-A1 | Substituted piperidines, medicaments containing these compounds, and methods for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-13 | — | — | US | disclosed |
| EP-0644892-A1 | INHIBITORS OF ANGIOTENSIN I CHYMASE(S) INCLUDING HUMAN HEART CHYMASE | PFIZER INC. (US) | 1995-03-29 | — | — | EP | disclosed |
| WO-1993025574-A1 | INHIBITORS OF ANGIOTENSIN I CHYMASE(S) INCLUDING HUMAN HEART CHYMASE | PFIZER INC. (US) | 1993-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | CHRM5 1450/4885ADRA2C 2577/4885ACHE 18/4885 |
| US-20030212057-A1 | Substituted piperidines, medicaments containing these compounds, and methods for the production thereof | CALCA, CALCRL, P2RY1 | CHRM5 441/4885ADRA2C 36/4885ACHE 1225/4885 |
| US-20080280870-A1 | Beta-Lactamyl Phenylalanine, Cysteine, and Serine Vasopressin Antagonists | AVPR2, AVPR1A, AVPR1B | CHRM5 2893/4885ADRA2C 41/4885ACHE 4065/4885 |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | GPX4, CRH, TXN | CHRM5 1888/4885ADRA2C 571/4885ACHE 362/4885 |
| US-20090170825-A1 | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | GABBR1, GABBR2, ALAD | CHRM5 1999/4885ADRA2C 484/4885ACHE 2132/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | CHRM5 322/4885ADRA2C 114/4885ACHE 98/4885 |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | CHRM5 322/4885ADRA2C 114/4885ACHE 98/4885 |
| US-11628160-B2 | Compositions and methods for treating brain injury | FABP7, PYGB, CHAT | CHRM5 1450/4885ADRA2C 2577/4885ACHE 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.